Abstract:Current prophylactic human immunodeficiency virus 1 (HIV-1) vaccine research aims to elicit broadly neutralizing antibodies (bnAbs). Membrane-proximal external region (MPER)-targeting bnAbs, such as 10E8, provide exceptionally broad neutralization, but some are autoreactive. Here, we generated humanized B cell antigen receptor knock-in mouse models to test whether a series of germline-targeting immunogens could drive MPER-specific precursors toward bnAbs. We found that recruitment of 10E8 precursors to germinal centers (GCs) required a minimum affinity for germline-targeting immunogens, but the GC residency of MPER precursors was brief due to displacement by higher-affinity endogenous B cell competitors. Higher-affinity germline-targeting immunogens extended the GC residency of MPER precursors, but robust long-term GC residency and maturation were only observed for MPER-HuGL18, an MPER precursor clonotype able to close the affinity gap with endogenous B cell competitors in the GC. Thus, germline-targeting immunogens could induce MPER-targeting antibodies, and B cell residency in the GC may be regulated by a precursor–competitor affinity gap.

What problem does this paper attempt to address?

The main issue this paper attempts to address is the development of an effective HIV vaccine, specifically the induction of broadly neutralizing antibodies (bnAbs). Specifically, the study focuses on the selection and maturation process of membrane-proximal external region (MPER)-specific precursor B cells in germinal centers (GCs). ### Background - **HIV Vaccine Development**: Current HIV vaccine research aims to induce the production of broadly neutralizing antibodies (bnAbs) that can neutralize multiple HIV strains. - **MPER-specific bnAbs**: MPER-specific bnAbs, such as 10E8, have broad neutralizing capabilities, but some antibodies may exhibit autoreactivity. - **Selection of Precursor B Cells**: To induce these bnAbs, it is necessary to select and activate specific precursor B cells and guide their maturation in germinal centers. ### Research Objectives - **Generation of Humanized Mouse Model**: Researchers generated a mouse model expressing human 10E8 precursor B cell receptors to test whether a series of germline-targeting immunogens can drive the development of MPER-specific precursor B cells into bnAbs. - **Exploration of Precursor B Cell Recruitment and Maturation**: The study focuses on how precursor B cells are recruited to germinal centers, their residency time, and the maturation process within these centers. ### Key Findings - **Affinity Requirements**: Recruitment of precursor B cells to germinal centers requires a certain minimum affinity for germline-targeting immunogens. - **Impact of Competition**: Due to competition from high-affinity endogenous B cells, MPER precursor B cells have a shorter residency time in germinal centers. - **Optimizing Immunogens**: By increasing the affinity of germline-targeting immunogens, the residency time of MPER precursor B cells in germinal centers can be extended. However, long-term residency and maturation were only observed in the MPER-HuGL18 clone, which can narrow the affinity gap with endogenous B cell competitors. ### Conclusion - **Role of Germline-Targeting Immunogens**: Germline-targeting immunogens can induce the production of MPER-specific antibodies, but the residency and maturation of B cells in germinal centers are regulated by the affinity gap between precursors and competitors. - **Future Directions**: The study provides important insights for designing more effective HIV vaccines, particularly on how to optimize immunogens to promote long-term residency and maturation of precursor B cells. Overall, this study reveals the challenges faced by precursor B cells in the selection and maturation process within germinal centers and proposes methods to overcome these challenges by optimizing immunogens. This provides a crucial theoretical foundation and technical support for future HIV vaccine development.

Affinity gaps among B cells in germinal centers drive the selection of MPER precursors

Vaccination induces broadly neutralizing antibody precursors to HIV gp41

Diverse competitor B cell responses to a germline-targeting priming immunogen in human Ig loci transgenic mice

Immunogenicity of a germline-targeting nanoparticle in knock-in mice expressing human B cell receptors of the HIV gp41 neutralizing antibody, DH511

Guiding the humoral response against HIV-1 toward a MPER adjacent region by immunization with a VLP-formulated antibody-selected envelope variant

Structural Basis for Broad HIV-1 Neutralization by the MPER-Specific Human Broadly Neutralizing Antibody LN01

Vaccine priming of rare HIV broadly neutralizing antibody precursors in nonhuman primates

Diverse priming outcomes under conditions of very rare precursor B cells

Anti–HIV-1 B cell responses are dependent on B cell precursor frequency and antigen-binding affinity

Membrane-bound mRNA immunogens lower the threshold to activate HIV Env V2 apex-directed broadly neutralizing B cell precursors in humanized mice

Amino acid substitution of the membrane-proximal external region alter neutralization sensitivity in a chronic HIV-1 clade B infected patient

Sequence Intrinsic Somatic Mutation Mechanisms Contribute to Affinity Maturation of Vrc01-Class Hiv-1 Broadly Neutralizing Antibodies

Identification of Non-Hiv Immunogens That Bind to Germline B12 Predecessors and Prime for Elicitation of Cross-Clade Neutralizing Hiv-1 Antibodies

mRNA-LNP HIV-1 trimer boosters elicit precursors to broad neutralizing antibodies

Preservation of memory B cell homeostasis in an individual producing broadly neutralising antibodies against HIV-1

The development of HIV vaccines targeting gp41 membrane-proximal external region (MPER): challenges and prospects

Germline-targeting HIV vaccination induces neutralizing antibodies to the CD4 binding site

Vaccination induces maturation in a mouse model of diverse unmutated VRC01-class precursors to HIV-neutralizing antibodies with >50% breadth

Targeted selection of HIV-specific antibody mutations by engineering B cell maturation

A Germline-Targeting Chimpanzee SIV Envelope Glycoprotein Elicits a New Class of V2-Apex Directed Cross-Neutralizing Antibodies

Developmental Pathway of the MPER-Directed HIV-1-Neutralizing Antibody 10E8.